Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques

Gerard Zurawski, Sandra Zurawski, Anne Laure Flamar, Laura Richert, Ralf Wagner, Georgia D. Tomaras, David C. Montefiori, Mario Roederer, Guido Ferrari, Christine Lacabaratz, Henri Bonnabau, Peter Klucar, Zhiqing Wang, Kathryn E. Foulds, Shing Fen Kao, Nicole L. Yates, Celia LaBranche, Bertram Jacobs, Karen Kibler, Benedikt AsbachAlexander Kliche, Andres Salazar, Steve Reed, Steve Self, Raphael Gottardo, Lindsey Galmin, Deborah Weiss, Anthony Cristillo, Rodolphe Thiebaut, Giuseppe Pantaleo, Yves Levy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccineinduced protective immunity in humans. Here we describe the first tests in non-human primates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is expressed on various antigen presenting cells and endothelial cells, and is involved in promoting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested for priming immune responses and boosting responses in animals primed with replication competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elicited robust cellular and humoral responses when used for either priming or boosting immunity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4 agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1 Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against various gp140 domains were cross-reactive across HIV-1 clades; however, the sera neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140 carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine, justify further exploration of this DC-targeting vaccine approach for protective immunity against HIV-1.

Original languageEnglish (US)
Article numbere0153484
JournalPLoS One
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Human immunodeficiency virus 1
Macaca mulatta
immune response
antigen-presenting cells
immunity
dendritic cells
humoral immunity
agonists
HIV-1
Bearings (structural)
proteins
T-lymphocytes
vaccines
recombinant antibodies
Immunity
Vaccinia virus
T-cells
Antigen-Presenting Cells
low density lipoprotein
animal behavior

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Zurawski, G., Zurawski, S., Flamar, A. L., Richert, L., Wagner, R., Tomaras, G. D., ... Levy, Y. (2016). Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques. PLoS One, 11(4), [e0153484]. https://doi.org/10.1371/journal.pone.0153484

Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques. / Zurawski, Gerard; Zurawski, Sandra; Flamar, Anne Laure; Richert, Laura; Wagner, Ralf; Tomaras, Georgia D.; Montefiori, David C.; Roederer, Mario; Ferrari, Guido; Lacabaratz, Christine; Bonnabau, Henri; Klucar, Peter; Wang, Zhiqing; Foulds, Kathryn E.; Kao, Shing Fen; Yates, Nicole L.; LaBranche, Celia; Jacobs, Bertram; Kibler, Karen; Asbach, Benedikt; Kliche, Alexander; Salazar, Andres; Reed, Steve; Self, Steve; Gottardo, Raphael; Galmin, Lindsey; Weiss, Deborah; Cristillo, Anthony; Thiebaut, Rodolphe; Pantaleo, Giuseppe; Levy, Yves.

In: PLoS One, Vol. 11, No. 4, e0153484, 01.04.2016.

Research output: Contribution to journalArticle

Zurawski, G, Zurawski, S, Flamar, AL, Richert, L, Wagner, R, Tomaras, GD, Montefiori, DC, Roederer, M, Ferrari, G, Lacabaratz, C, Bonnabau, H, Klucar, P, Wang, Z, Foulds, KE, Kao, SF, Yates, NL, LaBranche, C, Jacobs, B, Kibler, K, Asbach, B, Kliche, A, Salazar, A, Reed, S, Self, S, Gottardo, R, Galmin, L, Weiss, D, Cristillo, A, Thiebaut, R, Pantaleo, G & Levy, Y 2016, 'Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques', PLoS One, vol. 11, no. 4, e0153484. https://doi.org/10.1371/journal.pone.0153484
Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD et al. Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques. PLoS One. 2016 Apr 1;11(4). e0153484. https://doi.org/10.1371/journal.pone.0153484
Zurawski, Gerard ; Zurawski, Sandra ; Flamar, Anne Laure ; Richert, Laura ; Wagner, Ralf ; Tomaras, Georgia D. ; Montefiori, David C. ; Roederer, Mario ; Ferrari, Guido ; Lacabaratz, Christine ; Bonnabau, Henri ; Klucar, Peter ; Wang, Zhiqing ; Foulds, Kathryn E. ; Kao, Shing Fen ; Yates, Nicole L. ; LaBranche, Celia ; Jacobs, Bertram ; Kibler, Karen ; Asbach, Benedikt ; Kliche, Alexander ; Salazar, Andres ; Reed, Steve ; Self, Steve ; Gottardo, Raphael ; Galmin, Lindsey ; Weiss, Deborah ; Cristillo, Anthony ; Thiebaut, Rodolphe ; Pantaleo, Giuseppe ; Levy, Yves. / Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques. In: PLoS One. 2016 ; Vol. 11, No. 4.
@article{fdebd857b9d5446aa3cfc95db4375f95,
title = "Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques",
abstract = "Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccineinduced protective immunity in humans. Here we describe the first tests in non-human primates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is expressed on various antigen presenting cells and endothelial cells, and is involved in promoting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested for priming immune responses and boosting responses in animals primed with replication competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elicited robust cellular and humoral responses when used for either priming or boosting immunity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4 agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1 Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against various gp140 domains were cross-reactive across HIV-1 clades; however, the sera neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140 carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine, justify further exploration of this DC-targeting vaccine approach for protective immunity against HIV-1.",
author = "Gerard Zurawski and Sandra Zurawski and Flamar, {Anne Laure} and Laura Richert and Ralf Wagner and Tomaras, {Georgia D.} and Montefiori, {David C.} and Mario Roederer and Guido Ferrari and Christine Lacabaratz and Henri Bonnabau and Peter Klucar and Zhiqing Wang and Foulds, {Kathryn E.} and Kao, {Shing Fen} and Yates, {Nicole L.} and Celia LaBranche and Bertram Jacobs and Karen Kibler and Benedikt Asbach and Alexander Kliche and Andres Salazar and Steve Reed and Steve Self and Raphael Gottardo and Lindsey Galmin and Deborah Weiss and Anthony Cristillo and Rodolphe Thiebaut and Giuseppe Pantaleo and Yves Levy",
year = "2016",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0153484",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Targeting HIV-1 env gp140 to LOX-1 elicits immune responses in rhesus macaques

AU - Zurawski, Gerard

AU - Zurawski, Sandra

AU - Flamar, Anne Laure

AU - Richert, Laura

AU - Wagner, Ralf

AU - Tomaras, Georgia D.

AU - Montefiori, David C.

AU - Roederer, Mario

AU - Ferrari, Guido

AU - Lacabaratz, Christine

AU - Bonnabau, Henri

AU - Klucar, Peter

AU - Wang, Zhiqing

AU - Foulds, Kathryn E.

AU - Kao, Shing Fen

AU - Yates, Nicole L.

AU - LaBranche, Celia

AU - Jacobs, Bertram

AU - Kibler, Karen

AU - Asbach, Benedikt

AU - Kliche, Alexander

AU - Salazar, Andres

AU - Reed, Steve

AU - Self, Steve

AU - Gottardo, Raphael

AU - Galmin, Lindsey

AU - Weiss, Deborah

AU - Cristillo, Anthony

AU - Thiebaut, Rodolphe

AU - Pantaleo, Giuseppe

AU - Levy, Yves

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccineinduced protective immunity in humans. Here we describe the first tests in non-human primates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is expressed on various antigen presenting cells and endothelial cells, and is involved in promoting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested for priming immune responses and boosting responses in animals primed with replication competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elicited robust cellular and humoral responses when used for either priming or boosting immunity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4 agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1 Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against various gp140 domains were cross-reactive across HIV-1 clades; however, the sera neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140 carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine, justify further exploration of this DC-targeting vaccine approach for protective immunity against HIV-1.

AB - Improved antigenicity against HIV-1 envelope (Env) protein is needed to elicit vaccineinduced protective immunity in humans. Here we describe the first tests in non-human primates (NHPs) of Env gp140 protein fused to a humanized anti-LOX-1 recombinant antibody for delivering Env directly to LOX-1-bearing antigen presenting cells, especially dendritic cells (DC). LOX-1, or 1ectin-like oxidized low-density lipoprotein (LDL) receptor-1, is expressed on various antigen presenting cells and endothelial cells, and is involved in promoting humoral immune responses. The anti-LOX-1 Env gp140 fusion protein was tested for priming immune responses and boosting responses in animals primed with replication competent NYVAC-KC Env gp140 vaccinia virus. Anti-LOX-1 Env gp140 vaccination elicited robust cellular and humoral responses when used for either priming or boosting immunity. Co-administration with Poly ICLC, a TLR3 agonist, was superior to GLA, a TLR4 agonist. Both CD4+ and CD8+ Env-specific T cell responses were elicited by anti-LOX-1 Env gp140, but in particular the CD4+ T cells were multifunctional and directed to multiple epitopes. Serum IgG and IgA antibody responses induced by anti-LOX-1 Env gp140 against various gp140 domains were cross-reactive across HIV-1 clades; however, the sera neutralized only HIV-1 bearing sequences most similar to the clade C 96ZM651 Env gp140 carried by the anti-LOX-1 vehicle. These data, as well as the safety of this protein vaccine, justify further exploration of this DC-targeting vaccine approach for protective immunity against HIV-1.

UR - http://www.scopus.com/inward/record.url?scp=84964397371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964397371&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0153484

DO - 10.1371/journal.pone.0153484

M3 - Article

C2 - 27077384

AN - SCOPUS:84964397371

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0153484

ER -